EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - PDF

This is the final project plan of the Other Technologies CA on MammaPrint® - Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04)